Aclaris says FDA grants Fast Track status for modzatinib in moderate to severe lichen planus
ACRS•Phase 2b study expected in 2026
A phased, multi-part Phase 2b trial is expected to start in Q4 2026.
FDA grants Fast Track designation
Aclaris Therapeutics received FDA Fast Track designation for modzatinib (ATI-2138) in moderate to severe lichen planus.
The designation supports an expedited development and review path, including potential rolling NDA submission.
